Precision BioSciences, Inc.
$6.49
+7.5%Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.8).
Valuation inputs: P/E -1.8, earnings yield N/A, momentum +7.5%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -50.5%, ROIC -35.5%).
Profitability stack: net margin -1.4%, ROE -50.5%, ROIC -35.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +40.3%, momentum +7.5%, net margin -1.4%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Precision BioSciences, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Precision BioSciences, Inc. Fair Value Envelope
Precision BioSciences, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Precision BioSciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Precision BioSciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Precision BioSciences, Inc. Street Expectations Map
Wall Street analysts project that DTIL stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 19.00, with estimates ranging from a low of 19.00 to a high of 19.00.
The consensus 1-year price target stands at 19.00, with estimates ranging from a low of 19.00 to a high of 19.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Precision BioSciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $82K and sold $503K worth of DTIL shares, resulting in $421K of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
7.1K
33.71K
107.6K
431.27K
-398K
-$398K
6-9 Months
4.1K
20.27K
1.3K
8.46K
+12K
+$12K
9-12 Months
6.8K
28.08K
14.8K
63.16K
-35K
-$35K
Top Buyers
Frankel Stanley
Director
$26K
Buehler Kevin
Director
$21K
Brown Melinda
Director
$21K
Germano Geno J
Director
$14K
Top Sellers
Amoroso Michael
Director, Officer: President And Ceo
$224K
Kelly John Alexander
Officer: Chief Financial Officer
$164K
Smith J. Jefferson
Officer: Chief Research Officer
$60K
Scimeca Dario
Officer: General Counsel And Secretary
$55K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $421K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Insider Participation
4 insider buyers and 4 sellers. Equal participation suggests mixed or neutral insider views.
No Dividend Yield Data
DTIL has not reported any dividend yield values in the available annual periods.
dtil Dividend History
Learning Layer
Related Guides
Build conviction on DTIL by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.